The manufacturing of medicinal products is for us not only a matter of implementing a certain technological process, but a human mission based on high standards of quality, safety and efficacy of medications
Sofia, Bulgaria, December 20, 2023 - Pursuant to the requirements of Art. 100t of the Law on Public Offering of Securities, "Sopharma" AD (SFA: BSE AD, SPH: Warsaw Stock Exchange) announces that on the basis of Art. 187b of the Commercial Law and Art. 111, para. 5 and para.
Sofia, Bulgaria, December 20, 2023 – According to the requirements of art. 100t of LPOS, “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that for the month of November 2023, the Company realized a decrease in sales of 20% compared to the same month of the previous year, incl. 11% decrease in domestic sales and 26% decrease in export sales.
For the eleven months from the beginning of 2023, sales increased by a total of 14%, incl. a 3% increase in domestic sales and a 21% increase in export sales.
Sofia, Bulgaria, December 20 2023 – According to the requirements of art. 17 of the Regulation (EU) No 596/2014 of the European Parliament and of the Council, “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that on December 19, 2023 the Company bought 30 000 (thirty thousand) own shares representing 0.0174% of the share capital of the Company, at a total value of BGN 177 000,00 on the Bulgarian Stock Exchange, the average price per share was BGN 5,90.
Sofia, Bulgaria, December 19, 2023 - Pursuant to the requirements of Art. 100t of the Law on Public Offering of Securities, "Sopharma" AD (SFA: BSE AD, SPH: Warsaw Stock Exchange) announces that on the basis of Art. 187b of the Commercial Law and Art. 111, para. 5 and para.
Sofia, Bulgaria, December 18, 2023 - Pursuant to the requirements of Art. 100t of the Law on Public Offering of Securities, "Sopharma" AD (SFA: BSE AD, SPH: Warsaw Stock Exchange) announces that on the basis of Art. 187b of the Commercial Law and Art. 111, para. 5 and para.